Munich EUR

Intellia Therapeutics Inc (38I.MU)

6.18

-0.29

(-4.46%)

At close: 8:00:14 AM GMT+2

Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple

We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Intellia Therapeutics, Inc. (NASDAQ:NTLA) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the […]

Insider Monkey 8 days ago

NTLA
Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN

The trial is structured to assess the safety and efficacy of the therapy in approximately 50 ATTRv-PN subjects.

Clinical Trials Arena 13 days ago

NTLA
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on April 1, 2025, it awarded an inducement grant to three new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment. The inducement grant consisted of time-based restricted stock units (“RSUs”) for 8,400 shares of Intellia’s common stock,

GlobeNewswire 14 days ago

NTLA
IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility

If preclinical findings were translated into clinic, they could shorten CAR-T generation lead time to one day.

Pharmaceutical Technology 14 days ago

NTLA
Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient has been dosed in MAGNITUDE-2, a global, pivotal Phase 3 trial of nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). “We are pleased to have dosed the first patient with a treatment that has such stro

GlobeNewswire 14 days ago

NTLA
Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy?

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Intellia Therapeutics, Inc. (NASDAQ:NTLA) stands against other best gene-editing stocks to buy. Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to treat […]

Insider Monkey 16 days ago

NTLA
Biotech stocks slide as Marks resignation seen being negative for sector

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit

TipRanks 16 days ago

GLPG

GLPGF

PTCT
Intellia Focuses on Pipeline Development Amid Stiff Competition

Studies on NTLA's gene-edited therapy, nex-z, are progressing well while other pipelines are picking up pace. Stiff competition in the target market is a woe.

Zacks 17 days ago

NTLA

VRTX

REGN
NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication

The FDA bestows a Regenerative Medicine Advanced Therapy tag to Intellia's nex-z for treating transthyretin amyloidosis with cardiomyopathy.

Zacks 21 days ago

NTLA
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to nexiguran ziclumeran (nex-z, also known as NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM). “This is a meani

GlobeNewswire 22 days ago

NTLA
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

This aggressive growth investor is looking at the bright side when it's raining on Wall Street.

Motley Fool 27 days ago

TSLA

NTLA
Royal Caribbean upgraded, AppLovin downgraded: Wall Street's top analyst calls

Royal Caribbean upgraded, AppLovin downgraded: Wall Street's top analyst calls

The Fly last month

APP

RCL

NTLA
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

A week ago, Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) came out with a strong set of yearly numbers that could...

Simply Wall St. last month

NTLA
NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y

Intellia reports better-than-expected fourth-quarter 2024 results. The company provides updates on its pipeline candidates.

Zacks last month

NTLA
Intellia Therapeutics Full Year 2024 Earnings: Beats Expectations

Intellia Therapeutics ( NASDAQ:NTLA ) Full Year 2024 Results Key Financial Results Revenue: US$57.9m (up 60% from FY...

Simply Wall St. last month

NTLA
Intellia Therapeutics Inc (NTLA) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...

Intellia Therapeutics Inc (NTLA) reports robust pipeline progress and financial stability, despite increased R&D expenses and strategic restructuring.

GuruFocus.com last month

NTLA
Q4 2024 Intellia Therapeutics Inc Earnings Call

Q4 2024 Intellia Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents last month

NTLA
Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 6.06% and 45.95%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

NTLA
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE)Expect to complete enrollment of the HAELO study in the second half of 2025 and submit a Biologics License Application in the second half of 2026 to support plans for U.S. launch in 2027Enrollment in the pivotal Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in patients with transthyretin amyloidosis (ATTR) with cardiomyopathy continues to track ahead of projections; more than 550 total

GlobeNewswire last month

NTLA
Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Praxis Precision Medicines (PRAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

PRAX

NTLA

Performance Overview

Return	38I.MU	S&P 500 (^GSPC)
YTD	-45.82%	-10.18%
1-Year	-69.64%	+5.19%
3-Year	-89.25%	+20.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Intellia Therapeutics Inc (38I.MU)

Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple

Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy?

Biotech stocks slide as Marks resignation seen being negative for sector

Intellia Focuses on Pipeline Development Amid Stiff Competition

NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Royal Caribbean upgraded, AppLovin downgraded: Wall Street's top analyst calls

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y

Intellia Therapeutics Full Year 2024 Earnings: Beats Expectations

Intellia Therapeutics Inc (NTLA) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...

Q4 2024 Intellia Therapeutics Inc Earnings Call

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Performance Overview